Video

Looking Ahead: Ovarian Cancer Hopes for 2018

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond. He shares his excitement about trials that will further investigate the efficacy of PARP inhibitors, and focus on immunotherapy. He speaks with enthusiasm about the potential to “engineer immunity” by taking a person’s T-cells and redirecting them against tumor tissue.

Dorigo emphasizes the need for better diagnostic tools to detect ovarian cancer. “The survival rate in Stage 1 ovarian cancer, those cancers confined to the ovary, is over 90 percent,” he said. “If we can find technologies that allow us to find those ovarian cancers early on, I think we will make a huge step forward.”

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Image of Kumar.